Image

North America Liquid Biopsy Market – Industry Trends and Forecast to 2030

Healthcare

Image

North America Liquid Biopsy Market – Industry Trends and Forecast to 2030

  • Healthcare
  • Published Report
  • May 2023
  • North America
  • 350 Pages
  • No of Tables: 169
  • No of Figures: 56

North America Liquid Biopsy Market – Industry Trends and Forecast to 2030

Market Size in USD Billion

CAGR :  % Diagram

Diagram Forecast Period 2023–2030
Diagram Market Size (Base Year) USD MILLION
Diagram Market Size (Forecast Year) USD MILLION
Diagram CAGR %

Major Markets Players

  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

North America Liquid Biopsy Market, By Product (Instruments, Consumables & Accessories, Services & Software), Biomaker Type (Circulating Tumor Cells (CTCS), Circulating Cell-Free DNA (CFDNA), Cell-free RNA, Extracellular Vesicles, Exosomes, and Others), Sample Type (Blood Sample-Based, Urine Sample-Based, Saliva & Other Tissue Fluid Sample-Based, and Others), Analytical Type (Molecular, Proteomics, and Histology/Imaging), Application Type (Cancer Applications and Non-Cancer Applications), Clinical Application (Routine Screening, Patient Work-Up, Therapy Selection, Treatment Monitoring, Recurrence Monitoring, and Others), Technology (Multi-Gene Parallel Analysis, and Single-Gene Analysis), End User (Hospitals, Reference Laboratories, Diagnostic Centers, Research Centers & Academic Institutes, and Others), Distribution Channel (Direct Tender, Third Party Distributor, and Others) - Industry Trends and Forecast to 2030.

North America Liquid Biopsy Market

North America Liquid Biopsy Market Analysis and Insights

The increasing awareness of advanced diagnostic technology North America has enhanced the demand for the market. The rising healthcare expenditure for better health services also contributes to the market's growth. The major market players focus on various service launches and approvals during this crucial period. In addition, the increase in improved advancement of processes and techniques also contributes to the rising demand for liquid biopsy.

North America Liquid Biopsy MarketNorth America Liquid Biopsy Market

The North America liquid biopsy market is expected to grow in the forecast year due to the rise in market players and the availability of advanced services. Along with this, manufacturers are engaged in the developmental activity for launching novel services in the market. The increasing development in the field of advanced healthcare techniques is further boosting market growth.

However, difficulties such as the lack of standardized protocols and the lack of skilled professionals might hamper the growth of the North America liquid biopsy market in the forecast period.

Data Bridge Market Research analyzes that the North America liquid biopsy market is expected to grow at a CAGR of 15.9% during the forecast period of 2023 to 2030.

Report Metric

Details

Forecast Period

2023 to 2030

Base Year

2022

Historic Years

2021 (Customizable to 2015- 2020)

Quantitative Units

Revenue in Million, Volumes in Units, Pricing in USD

Segments Covered

Product (Instruments, Consumables & Accessories, Services & Software), Biomaker Type (Circulating Tumor Cells (CTCS), Circulating Cell-Free DNA (CFDNA), Cell-free RNA, Extracellular Vesicles, Exosomes, and Others), Sample Type (Blood Sample-Based, Urine Sample-Based, Saliva & Other Tissue Fluid Sample-Based, and Others), Analytical Type (Molecular, Proteomics, and Histology/Imaging), Application Type (Cancer Applications and Non-Cancer Applications), Clinical Application (Routine Screening, Patient Work-Up, Therapy Selection, Treatment Monitoring, Recurrence Monitoring, and Others), Technology (Multi-Gene Parallel Analysis, and Single-Gene Analysis), End User (Hospitals, Reference Laboratories, Diagnostic Centers, Research Centers & Academic Institutes, and Others), Distribution Channel (Direct Tender, Third Party Distributor, and Others)

Countries Covered

U.S., Canada, and Mexico

Market Players Covered

F. Hoffmann-La Roche Ltd, Guardant Health, Thermo Fisher Scientific Inc., Exact Sciences Corporation(Genomic health), QIAGEN, Labcorp, Johnson & Johnson Services, Inc., Illumina Inc, mdxhealth, NeoGenomics Laboratories, Bio-Rad Laboratories, Inc., Natera, Inc., CARDIFF ONCOLOGY, INC., PathAI, STRECK, BIOCEPT, INC., Sysmex Inostics Inc., Fluxion Biosciences Inc, Epic Sciences, and Predicine, ANGLE plc, Oncocyte Corporation among others

Market Definition

A liquid biopsy is a medical test that involves the analysis of various biomolecules, such as DNA, RNA, proteins, and other substances in a patient's blood or other bodily fluids, to diagnose and monitor various medical conditions, including cancer. Unlike traditional biopsies that involve the removal of tissue samples from the body, a liquid biopsy is non-invasive and can provide important diagnostic information without the need for surgery or other invasive procedures. Liquid biopsies are still in the early stages of development but hold promise for improving the detection and management of cancer and other diseases.

North America Liquid Biopsy Market Dynamics

This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below

Drivers

  • Growing demand for non-invasive liquid biopsy technique

Liquid biopsies consist of isolating tumor-derived entities such as circulating tumor cells, circulating tumor DNA, and tumor extracellular vesicles among others, present in the body fluids of patients with cancer, followed by an analysis of genomic and proteomic data contained within them. Methods for isolation and analysis of liquid biopsies have rapidly evolved over the past few years, as described in the review, thus providing greater details about tumor characteristics such as mutations, tumor staging, tumor progression, heterogeneity, and gene and clonal evolution, among others. Liquid biopsies from cancer patients have opened up newer avenues in detection and continuous monitoring, treatment based on precision medicine, and screening of markers for therapeutic resistance. Non-invasive cancer diagnostics offer a safer and more patient-friendly approach, resulting in a growing demand for these methods.

  • Advancements in precision medicine due to liquid biopsy

Precision medical oncology in the clinical management of cancer may be achieved through the diagnostic platform called "liquid biopsy" (LB). The LB was recognized as a powerful real-time approach for the molecular monitoring of this dynamic cancer disease. This method utilizes the detection of Biomakers in blood for prognostic and predictive purposes by non-invasive means, which in the near future will represent a change in the paradigm of molecular biology understanding and the heterogeneity of tumors. Advancements in precision medicine, fueled by the use of liquid biopsy techniques, have contributed significantly to the growing demand for non-invasive cancer diagnostics. Liquid biopsy techniques, such as the analysis of circulating tumor DNA (ctDNA), Circulating Tumor Cells (CTCs), or exosomes in blood or other body fluids, provide valuable information about the genetic makeup of tumors, enabling precision medicine approaches in cancer care.

Opportunity

  • Integration of Artificial Intelligence (AI) and machine learning

Liquid biopsy-based approaches offer many new opportunities to measure molecular Biomakers for diagnosing, prognosis, and monitoring disease. Artificial Intelligence (AI), such as machine learning, and its ability to identify signatures of specific disease states in multiplexed data will be key to taking advantage of the new molecular information that microchip-based diagnostics can extract.

Thus, the integration of AI and machine learning is expected to act as an opportunity for the growth of the market.

  • Increasing reimbursements and government support for liquid biopsy

The adoption of liquid biopsy has been significantly influenced by government backing. Governments throughout the world have put legislation in place to encourage the adoption of liquid biopsy because they understand how it may enhance patient care, lower healthcare costs, and advance precision medicine. Incorporating liquid biopsy into national cancer screening programs or treatment recommendations is only one example of how this might be done. Other examples include financing for research and development of liquid biopsy technologies and backing clinical trials and studies to produce evidence on their therapeutic efficacy. Such government assistance has aided in boosting liquid biopsy test knowledge, adoption, and reimbursement coverage.

Thus, increasing reimbursements and government support for liquid biopsy is expected to act as an opportunity for the market's growth.

Restraint/Challenge

  • High cost of liquid biopsy tests

The liquid biopsy is severely constrained by the high cost. While liquid biopsy tests show promise for non-invasive illness detection and monitoring, including cancer, there are cost-related obstacles that may prevent their widespread use.

The necessity for specialized tools and technologies is one of the biggest economic obstacles. Costly tools, including digital PCR machines, NGS platforms, and automated sample processing systems, are frequently needed for liquid biopsy studies. Smaller healthcare facilities with tighter budgets may find it difficult to afford the initial investment and ongoing maintenance costs connected with these technologies, which limits their capacity to provide liquid biopsy tests to patients.

Thus, the high cost of liquid biopsy tests is expected to restrain the market's growth.

  • Lack of skilled professionals performing liquid biopsy

The demand for liquid biopsy tests is increasing due to their potential clinical utility in cancer detection, monitoring, and personalized treatment decision-making. However, there may be limited resources, including personnel, equipment, and funding, to support the implementation of liquid biopsy programs in healthcare institutions. This can result in a shortage of skilled professionals who can perform liquid biopsy tests, especially in regions or healthcare settings with limited resources.

Thus, the lack of skilled professionals performing liquid biopsies is expected to challenge the market growth.

Recent Development

  • In January 2022, Exact Sciences Corporation announced the acquisition of Prevention Genetics, a genetic testing laboratory, to complement its advanced cancer diagnostics portfolio and support its entrance into hereditary cancer testing (HCT).

North America Liquid Biopsy Market Scope

The North America liquid biopsy market is categorized into nine notable segments which are product, Biomaker type, sample type, analytical type, application type, clinical application, technology, end user, and distribution channel. The growth amongst these segments will help you analyze market growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product

  • Instruments
  • Consumables & Accessories
  • Services & Software

On the basis of product, the market is segmented into instruments, consumables & accessories, services & software.

Biomaker Type

  • Circulating Tumor Cells (CTCS)
  • Circulating Cell-Free DNA (CFDNA)
  • Cell-Free RNA
  • Exosomes
  • Extracellular vesicles
  • Others

On the basis of biomaker type, the market is segmented into circulating tumor cells (CTCS), circulating cell-free DNA (CFDNA), cell-free RNA, extracellular vesicles, exosomes, and others.

Sample Type

  • Blood Sample-Based
  • Urine Sample-Based
  • Saliva & Other Tissue Fluids Sample-Based
  • Others

On the basis of sample type, the market is segmented into blood sample-based, urine sample-based, saliva & other tissue fluid sample-based, and others.

Analytical Type

  • Molecular
  • Proteomic
  • Histology/Imaging

On the basis of analytical type, the market is segmented into molecular, proteomics, and histology/imaging.

Application Type

  • Cancer Applications
  • Non-Cancer Applications

On the basis of application type, the market is segmented into cancer applications and non-cancer applications.

Clinical Application

  • Routine Screening
  • Therapy Selection
  • Treatment Monitoring
  • Recurrence Monitoring
  • Patient Work-Up
  • Others

On the basis of clinical application, the market is segmented into routine screening, patient work-up, therapy selection, treatment monitoring, recurrence monitoring, and others.

Technology

  • Multi-Gene-Parallel Analysis
  • Single Gene Analysis

On the basis of technology, the market is segmented into multi-gene parallel analysis and single-gene analysis.

End User

  • Hospitals
  • Reference Laboratories
  • Diagnostics Centers
  • Research Centres and Academic Institutes
  • Others

On the basis of end user, the market is segmented into hospitals, reference laboratories, diagnostic centers, research centers & academic institutes, and others.

Distribution Channels

  • Direct Tender
  • Third Party Distributor
  • Others

On the basis of distribution channel, the market is segmented into direct tender, third party distributor, and others.

Liquid Biopsy Market

North America Liquid Biopsy Market Regional Analysis/Insights

The North America liquid biopsy market is analyzed, and market size insights and trends are provided based on product, biomaker type, sample type, analytical type, application type, clinical application, technology, end user, and distribution channel.

The countries covered in this market report are U.S., Canada, and Mexico.

In 2023, U.S. is expected to dominate the North America liquid biopsy market due to the growing demand for non-invasive cancer diagnostics.

The country section of the report also provides individual market-impacting factors and changes in market regulation that impact the current and future trends of the market. Data points such as downstream and upstream value chain analysis, technical trends, Porter's five forces analysis, and case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands and the impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Competitive Landscape and North America Liquid Biopsy Market Share Analysis

The North America liquid biopsy market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, North America presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, brand analysis, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to the North America liquid biopsy market.

Some of the major players in the North America liquid biopsy market are F. Hoffmann-La Roche Ltd, Guardant Health, Thermo Fisher Scientific Inc., Exact Sciences Corporation(Genomic health), QIAGEN, Labcorp, Johnson & Johnson Services, Inc., Illumina Inc, mdxhealth, NeoGenomics Laboratories, Bio-Rad Laboratories, Inc., Natera, Inc., CARDIFF ONCOLOGY, INC., PathAI, STRECK, BIOCEPT, INC., Sysmex Inostics Inc., Fluxion Biosciences Inc, Epic Sciences, and Predicine, ANGLE plc, Oncocyte Corporation among others.


SKU-

TABLE 1 WAYS IN WHICH LIQUID BIOPSY HAS ADVANCED PRECISION MEDICINE

TABLE 2 NORTH AMERICA LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 3 NORTH AMERICA CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 4 NORTH AMERICA CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 5 NORTH AMERICA TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 6 NORTH AMERICA COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 7 NORTH AMERICA ASSAYS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 8 NORTH AMERICA INSTRUMENTS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 9 NORTH AMERICA INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 10 NORTH AMERICA SERVICES & SOFTWARE IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 11 NORTH AMERICA SERVICES & SOFTWARE IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 12 NORTH AMERICA LIQUID BIOPSY MARKET, BY BIOMAKER TYPE, 2021-2030 (USD MILLION)

TABLE 13 NORTH AMERICA CIRCULATING TUMOR CELLS (CTCS) IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 14 NORTH AMERICA CIRCULATING CELL-FREE DNA (CFDNA) IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 15 NORTH AMERICA CELL-FREE RNA IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 16 NORTH AMERICA EXOSOMES IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 17 NORTH AMERICA EXTRACELLULAR VESICLES IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 18 NORTH AMERICA OTHERS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 19 NORTH AMERICA LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 20 NORTH AMERICA BLOOD SAMPLE-BASED IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 21 NORTH AMERICA URINE SAMPLE-BASED IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 22 NORTH AMERICA SALIVA & OTHER TISSUE FLUIDS SAMPLE-BASED IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 23 NORTH AMERICA OTHERS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 24 NORTH AMERICA LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)

TABLE 25 NORTH AMERICA MOLECULAR IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 26 NORTH AMERICA MOLECULAR IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)

TABLE 27 NORTH AMERICA PROTEOMIC IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 28 NORTH AMERICA PROTEOMIC IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)

TABLE 29 NORTH AMERICA HISTOLOGY/IMAGING IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 30 NORTH AMERICA LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 31 NORTH AMERICA CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 32 NORTH AMERICA CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 33 NORTH AMERICA BREAST IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 34 NORTH AMERICA NON-CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 35 NORTH AMERICA NON-CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 36 NORTH AMERICA LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)

TABLE 37 NORTH AMERICA ROUTINE SCREENING IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 38 NORTH AMERICA THERAPY SELECTION IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 39 NORTH AMERICA TREATMENT MONITORING IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 40 NORTH AMERICA TREATMENT MONITORING IN LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)

TABLE 41 NORTH AMERICA RECURRENCE MONITORING IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 42 NORTH AMERICA PATIENT WORK-UP IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 43 NORTH AMERICA OTHERS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 44 NORTH AMERICA LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 45 NORTH AMERICA MULTI-GENE-PARALLEL ANALYSIS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 46 NORTH AMERICA SINGLE GENE ANALYSIS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 47 NORTH AMERICA LIQUID BIOPSY MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 48 NORTH AMERICA HOSPITALS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 49 NORTH AMERICA REFERENCE LABORATORIES IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 50 NORTH AMERICA DIAGNOSTICS CENTERS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 51 NORTH AMERICA RESEARCH CENTRES AND ACADEMIC INSTITUTES IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 52 NORTH AMERICA OTHERS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 53 NORTH AMERICA LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 54 NORTH AMERICA DIRECT TENDER IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 55 NORTH AMERICA THIRD PARTY DISTRIBUTOR IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 56 NORTH AMERICA OTHERS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 57 NORTH AMERICA LIQUID BIOPSY MARKET, BY COUNTRY, 2021-2030 (USD MILLION)

TABLE 58 NORTH AMERICA LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 59 NORTH AMERICA CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 60 NORTH AMERICA CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 61 NORTH AMERICA TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 62 NORTH AMERICA TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 63 NORTH AMERICA COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 64 NORTH AMERICA COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 65 NORTH AMERICA ASSAYS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 66 NORTH AMERICA INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 67 NORTH AMERICA INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 68 NORTH AMERICA SERVICES & SOFTWARE IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 69 NORTH AMERICA LIQUID BIOPSY MARKET, BY BIOMAKER TYPE, 2021-2030 (USD MILLION)

TABLE 70 NORTH AMERICA LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 71 NORTH AMERICA LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)

TABLE 72 NORTH AMERICA MOLECULAR IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)

TABLE 73 NORTH AMERICA PROTEOMIC IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)

TABLE 74 NORTH AMERICA LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 75 NORTH AMERICA CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 76 NORTH AMERICA BREAST IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 77 NORTH AMERICA NON-CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 78 NORTH AMERICA LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)

TABLE 79 NORTH AMERICA TREATMENT MONITORING IN LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)

TABLE 80 NORTH AMERICA LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 81 NORTH AMERICA LIQUID BIOPSY MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 82 NORTH AMERICA LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 83 U.S. LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 84 U.S. CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 85 U.S. CONSUMABLE & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 86 U.S. LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)

TABLE 87 U.S. TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 88 U.S. TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 89 U.S. TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)

TABLE 90 U.S. COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 91 U.S. COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 92 U.S. COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)

TABLE 93 U.S. ASSAYS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 94 U.S. INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 95 U.S. INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 96 U.S. INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)

TABLE 97 U.S. SERVICES & SOFTWARE IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 98 U.S. LIQUID BIOPSY MARKET, BY BIOMAKER TYPE, 2021-2030 (USD MILLION)

TABLE 99 U.S. LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 100 U.S. LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)

TABLE 101 U.S. MOLECULAR IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)

TABLE 102 U.S. PROTEOMIC IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)

TABLE 103 U.S. LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 104 U.S. CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 105 U.S. BREAST IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 106 U.S. NON-CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 107 U.S. LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)

TABLE 108 U.S. TREATMENT MONITORING IN LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)

TABLE 109 U.S. LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 110 U.S. LIQUID BIOPSY MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 111 U.S. LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 112 CANADA LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 113 CANADA CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 114 CANADA CONSUMABLE & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 115 CANADA LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)

TABLE 116 CANADA TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 117 CANADA TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 118 CANADA TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)

TABLE 119 CANADA COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 120 CANADA COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 121 CANADA COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)

TABLE 122 CANADA ASSAYS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 123 CANADA INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 124 CANADA INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 125 CANADA INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)

TABLE 126 CANADA SERVICES & SOFTWARE IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 127 CANADA LIQUID BIOPSY MARKET, BY BIOMAKER TYPE, 2021-2030 (USD MILLION)

TABLE 128 CANADA LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 129 CANADA LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)

TABLE 130 CANADA MOLECULAR IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)

TABLE 131 CANADA PROTEOMIC IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)

TABLE 132 CANADA LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 133 CANADA CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 134 CANADA BREAST IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 135 CANADA NON-CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 136 CANADA LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)

TABLE 137 CANADA TREATMENT MONITORING IN LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)

TABLE 138 CANADA LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 139 CANADA LIQUID BIOPSY MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 140 CANADA LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 141 MEXICO LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 142 MEXICO CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 143 MEXICO CONSUMABLE & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 144 MEXICO LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)

TABLE 145 MEXICO TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 146 MEXICO TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 147 MEXICO TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)

TABLE 148 MEXICO COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 149 MEXICO COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 150 MEXICO COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)

TABLE 151 MEXICO ASSAYS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 152 MEXICO INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 153 MEXICO INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 154 MEXICO INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)

TABLE 155 MEXICO SERVICES & SOFTWARE IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 156 MEXICO LIQUID BIOPSY MARKET, BY BIOMAKER TYPE, 2021-2030 (USD MILLION)

TABLE 157 MEXICO LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 158 MEXICO LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)

TABLE 159 MEXICO MOLECULAR IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)

TABLE 160 MEXICO PROTEOMIC IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)

TABLE 161 MEXICO LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 162 MEXICO CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 163 MEXICO BREAST IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 164 MEXICO NON-CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 165 MEXICO LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)

TABLE 166 MEXICO TREATMENT MONITORING IN LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)

TABLE 167 MEXICO LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 168 MEXICO LIQUID BIOPSY MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 169 MEXICO LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

FREQUENTLY ASK QUESTIONS

The North America Liquid Biopsy Market is projected to grow at a CAGR of 15.9% during the forecast period by 2030.
The North America Liquid Biopsy Market is segmented on the basis of product, Biomaker type, sample type, analytical type, application type, clinical application, technology, end user, and distribution channel.
The major players in the North America Liquid Biopsy Market are F. Hoffmann-La Roche Ltd, Guardant Health, Thermo Fisher Scientific Inc., QIAGEN, Labcorp, Johnson & Johnson Services, Inc., Illumina Inc, mdxhealth, NeoGenomics Laboratories, Bio-Rad Laboratories, Inc., etc.
The countries covered in the North America Liquid Biopsy Market are U.S., Canada, and Mexico.
Free Sample Report

CHOOSE LICENCE TYPE

  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials